Article

LIVE BROADCAST: A New Targeted Therapy For Ovarian Cancer

In an upcoming broadcast, key opinion leaders will discuss clinical efficacy and safety data for a new targeted therapy.

To explore unmet needs for patients with ovarian cancer and obtain expert perspective, watch the live broadcast on 12/14, 6:00pm EST, 12/15, 7:00pm EST and 1/12/23, 8:00pm EST. To register for the event, visit https://studio.mjhassoc.com/reach/National-Broadcast.

US-UNB-2200017 10/22

Related Videos
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Related Content
The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
November 25th 2024

FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Mirdametinib in Adult and Pediatric NF1-PN | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

Biomarkers in Diffuse Large B-cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes
November 25th 2024

Biomarkers in Diffuse Large B-cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes

FDA
November 25th 2024

FDA Approves Companion Diagnostic for Zanidatamab in HER2+ Biliary Tract Cancer

Capivasertib Plus Abiraterone/ADT in PTEN-Deficient mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC